These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23228808)

  • 1. Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability.
    Hu Y; Zhu J; Chan KH; Wong YH
    Bioorg Med Chem; 2013 Jan; 21(2):547-52. PubMed ID: 23228808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands.
    Hu Y; Ho MK; Chan KH; New DC; Wong YH
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2582-5. PubMed ID: 20227878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
    Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.
    Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C
    Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.
    Rivara S; Vacondio F; Fioni A; Silva C; Carmi C; Mor M; Lucini V; Pannacci M; Caronno A; Scaglione F; Gobbi G; Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G
    ChemMedChem; 2009 Oct; 4(10):1746-55. PubMed ID: 19728346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivity.
    Markl C; Clafshenkel WP; Attia MI; Sethi S; Witt-Enderby PA; Zlotos DP
    Arch Pharm (Weinheim); 2011 Oct; 344(10):666-74. PubMed ID: 21887801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.
    Spadoni G; Bedini A; Lucarini S; Mari M; Caignard DH; Boutin JA; Delagrange P; Lucini V; Scaglione F; Lodola A; Zanardi F; Pala D; Mor M; Rivara S
    J Med Chem; 2015 Sep; 58(18):7512-25. PubMed ID: 26334942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.
    Rivara S; Pala D; Lodola A; Mor M; Lucini V; Dugnani S; Scaglione F; Bedini A; Lucarini S; Tarzia G; Spadoni G
    ChemMedChem; 2012 Nov; 7(11):1954-64. PubMed ID: 22927210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(Phenoxyalkyl)amides as MT(1) and MT(2) ligands: antioxidant properties and inhibition of Ca(2+)/CaM-dependent kinase II.
    Carocci A; Catalano A; Bruno C; Lovece A; Roselli MG; Cavalluzzi MM; De Santis F; De Palma A; Rusciano MR; Illario M; Franchini C; Lentini G
    Bioorg Med Chem; 2013 Feb; 21(4):847-51. PubMed ID: 23332368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
    Hu Y; Chan KH; He X; Ho MK; Wong YH
    PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
    Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
    Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor.
    Chan KH; Hu Y; Ho MK; Wong YH
    Curr Med Chem; 2013; 20(2):289-300. PubMed ID: 23131177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands.
    Spadoni G; Bedini A; Guidi T; Tarzia G; Lucini V; Pannacci M; Fraschini F
    ChemMedChem; 2006 Oct; 1(10):1099-105. PubMed ID: 16955531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.